Ropivacaine


Amide local anesthetic (S-enantiomer propyl analog)

The (S)-propyl analog of bupivacaine and mepivacaine, marketed as Naropin, with reduced cardiotoxicity and motor-sparing sensory block profile.

Abstract

Ropivacaine ((S)-1-propyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 84057-95-4; molecular formula C17H26N2O; molecular weight 274.40) is an amide local anesthetic developed at AB Astra in the 1990s and approved by the FDA in 1996 (Naropin). The compound is structurally intermediate between mepivacaine (propyl chain, racemic) and bupivacaine (butyl chain, racemic): ropivacaine carries the propyl substituent like mepivacaine but is sold as a single (S)-enantiomer. The shorter alkyl chain reduces lipid solubility relative to bupivacaine, contributing to a less profound motor block at concentrations producing equivalent sensory block (the so-called motor-sparing property exploited in obstetric epidural analgesia and ambulatory regional anesthesia). The (S)-enantiomer purity confers a cardiotoxicity profile favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Mechanism is voltage-gated sodium channel block with state-dependent kinetics. Onset is 5 to 15 minutes for infiltration and peripheral nerve block; duration is 3 to 6 hours, generally somewhat shorter than bupivacaine at equivalent doses. The motor-sparing profile drives ropivacaine selection in obstetric epidural at low concentrations (0.0625 to 0.125 percent) where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor function recovery before discharge is operationally important. Lipid emulsion rescue applies to any LAST event with ropivacaine as for other long-acting amides.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph